bacampicillin (spectrobid) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Bacampicillin is a penicillin antibiotic. It is a prodrug of ampicillin with improved oral bioavailability. It exerts bactericidal activity via inhibition of bacterial cell wall synthesis by binding one or more of the penicillin binding proteins (PBPs). Spectrobid is used to treat bacterial infections such as tonsillitis, pneumonia (lung infection), bronchitis (inflammation of airway), urinary tract infections, gonorrhea, and infections of the skin. Adverse effects are: anemia, thrombocytopenia, neutropenia, agranulocytosis, seizures, nephrotoxicity, Jarisch-Herxheimer Reaction (fever, chills, sweating, tachycardia, hyperventilation, flushing, and myalgia). Drug interactions: Contraceptives - decreased contraceptive effectiveness; Live Typhoid Vaccine - decreased immunological response to the typhoid vaccine; Probenecid - increased bacampicillin levels.   NCATS

Chemistry

  • SMILES: CCOC(=O)OC(C)OC(=O)[C@@H]1N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1(C)C
  • InChIKey: PFOLLRNADZZWEX-FFGRCDKISA-N
  • Mol. Mass: 465.53
  • ALogP: 1.3
  • ChEMBL Molecules:
    bacampicillin  
    bacampicillin hydrochloride  
More Chemistry

Pharmacology

Alternative names

1-[(ethoxycarbonyl)oxy]ethyl (2s,5r,6r)-6-{[(2r)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate | 1'-ethoxycarbonyloxyethyl-(6-d-alpha-aminophenylacetamido)penicillanate | ambaxin | bacampicilina | bacampicillin | bacampicilline | bacampicillin hcl | bacampicillin hydrochloride | bacampicillin monohydrochloride | bacampicillinum | bacampicine | carampicillin | ethoxycarbonyloxyethyl ester of ampicillin | penglobe | spectrobid

Organizations (5)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (6)


 

Bronchitis (approved 1980)

Gonorrhea (approved 1980)

Pneumonia (approved 1980)

Skin Diseases, Bacterial (approved 1980)

Tonsillitis (approved 1980)

Urinary Tract Infections (approved 1980)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Acne Vulgaris (Phase 3)

Osteomyelitis (Early Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue